Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial - Kristeleit, R; Lisyanskaya, A; Fedenko, A (Lancet Oncol, 2022)